In this episode, Professor Escudier from Gustave Roussy, a major cancer center in Paris France, discusses the advances in kidney cancer treatment over the past 30 years. Professor Escudier discusses the significance of the Keynote 564, the first positive trial in adjuvant renal cell cancer. He explains how these findings impact first-line treatment decisions for metastatic kidney cancer. He discusses the differences between cure, complete response and the role of the MDT, clinical and pathological biomarkers in treatment selection. Professor Escudier especially covers the questions that he patient should their doctors concerning their renal cancer and defines the differences between Clear Cell and Non-Clear Cell renal cancer treatment outcomes and expectations.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com